Wells Fargo & Company Cure Vac N.V. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Cure Vac N.V. stock. As of the latest transaction made, Wells Fargo & Company holds 1,684 shares of CVAC stock, worth $4,563. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,684

Previous 3,351 49.75%

Holding current value

$4,563

Previous $10,000 50.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.31 - $4.99 $3,850 - $8,318	-1,667 Reduced 49.75%	1,684 $5,000
Q1 2024 May 10, 2024	BUY	$2.94 - $4.34 $8,940 - $13,197	3,041 Added 980.97%	3,351 $10,000
Q3 2023 Nov 13, 2023	SELL	$6.5 - $10.77 $585 - $969	-90 Reduced 22.5%	310 $2,000
Q2 2023 Aug 15, 2023	SELL	$6.69 - $12.25 $2,676 - $4,900	-400 Reduced 50.0%	400 $4,000
Q1 2023 May 12, 2023	SELL	$6.38 - $12.5 $644 - $1,262	-101 Reduced 11.21%	800 $5,000
Q4 2022 Feb 13, 2023	BUY	$5.75 - $8.5 $575 - $850	100 Added 12.48%	901 $5,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $3,351 - $6,827	-448 Reduced 35.87%	801 $7,000
Q2 2022 Aug 12, 2022	BUY	$13.18 - $19.41 $10,952 - $16,129	831 Added 198.8%	1,249 $17,000
Q1 2022 May 16, 2022	SELL	$14.73 - $35.25 $3,815 - $9,129	-259 Reduced 38.26%	418 $8,000
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $9,273 - $13,260	275 Added 68.41%	677 $24,000
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $14,778 - $22,350	-300 Reduced 42.74%	402 $22,000
Q2 2021 Aug 16, 2021	SELL	$56.91 - $127.53 $42,454 - $95,137	-746 Reduced 51.52%	702 $51,000
Q1 2021 May 13, 2021	BUY	$79.79 - $126.29 $92,396 - $146,243	1,158 Added 399.31%	1,448 $132,000
Q4 2020 Feb 09, 2021	BUY	$46.76 - $136.27 $1,870 - $5,450	40 Added 16.0%	290 $24,000
Q3 2020 Nov 05, 2020	BUY	$43.8 - $77.2 $10,950 - $19,300	250 New	250 $12,000

Others Institutions Holding CVAC

# of Institutions

Shares Held

14.4M

Call Options Held

241K

Put Options Held

419K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $508M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Cure Vac N.V. Transaction History